Philip Kantoff

Company: Convergent Therapeutics

Job title: Chief Executive Officer & Co-Founder

Seminars:

Update on PSMA-Directed Actinium Labeled Radioantibody Therapy 1:15 pm

Exploring the rationale for using antibodies when targeting PSMA with Actinium-225 Uncovering activity of CONV01-a monotherapy in advanced prostate cancer Sharing activity of CONV01- a combination therapies in advanced prostate cancerRead more

day: Day Two ESC PM

A Personalized Future: Tailoring the Optimal Patient Care 2:00 pm

Explore the potential of personalized approach in radiopharmaceutical therapies and the obstacles to its broader adoption. With the unique opportunity to take advantage of dosimetry data, the industry is exploring how the next TRPs can be individually adapted. Explore future perspectives for tailored treatments by joining this workshop: Use dosimetry to guide personalized treatment and…Read more

day: Workshop F